P-Rex1 is dispensable for Erk activation and mitogenesis in breast cancer.

P-Rex1 is dispensable for Erk activation and mitogenesis in breast cancer. Oncotarget. 2018 Jun 19;9(47):28612-28624 Authors: Barrio-Real L, Lopez-Haber C, Casado-Medrano V, Goglia AG, Toettcher JE, Caloca MJ, Kazanietz MG Abstract Phosphatidylinositol-3,4,5-Trisphosphate Dependent Rac Exchange Factor 1 (P-Rex1) is a key mediator of growth factor-induced activation of Rac1, a small GTP-binding protein widely implicated in actin cytoskeleton reorganization. This Guanine nucleotide Exchange Factor (GEF) is overexpressed in human luminal breast cancer, and its expression associates with disease progression, metastatic dissemination and poor outcome. Despite the established contribution of P-Rex1 to Rac activation and cell locomotion, whether this Rac-GEF has any relevant role in mitogenesis has been a subject of controversy. To tackle the discrepancies among various reports, we carried out an exhaustive analysis of the potential involvement of P-Rex1 on the activation of the mitogenic Erk pathway. Using a range of luminal breast cancer cellular models, we unequivocally showed that silencing P-Rex1 (transiently, stably, using multiple siRNA sequences) had no effect on the phospho-Erk response upon stimulation with growth factors (EGF, heregulin, IGF-I) or a GPCR ligand (SDF-1). The lack of involvement of P-Rex1 in Erk activation was confirmed at the single cell level using a fluorescent biosensor of Erk kinase activity. Depletion of P-Rex1 from breast cancer ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Related Links:

In this study, three non-linear indices consist of compression, one-dimensional (1D) and two-dimensional (2D) fractal dimensions are used for the determination of the malignancy or benignity of cancer tumours in breast thermograms. On the other hand, by developing the high-precision infrared cameras as well as new methods of image processing, biomedical thermography images have found a prominent position among the others. Furthermore, cancerous tissue can be affected by the laser. In this study, in order to treat the cancerous lesion identified by breast thermograms, the laser parameters are designed. The basis of controll...
Source: IET Systems Biology - Category: Biology Source Type: research
Authors: Adamo B, Ricciardi GRR, Ieni A, Franchina T, Fazzari C, Sanò MV, Angelico G, Caruso M, Tuccari G, Adamo V Abstract [This corrects the article DOI: 10.18632/oncotarget.20293.]. PMID: 30783520 [PubMed - in process]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Lambertini M, Viglietti G PMID: 30783509 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Publication date: Available online 20 February 2019Source: Pharmacological ResearchAuthor(s): Yueyang Zhang, Binhua Zou, Yanhui Tan, Jianbing Su, Yiyuan Wang, Jialan Xu, Lei Tao, Hua Zhou, Liang Liu, Xiaojuan LiAbstractSinomenine (SIN) is an anti-inflammatory and antiarthritic alkaloid derived from Sinomenium acutum, and the product Zhengqing Fengtongning produced from SIN has been marketed in China for treating rheumatoid arthritis (RA). Interestingly, we recently found that SIN could significantly ameliorate bone destruction induced by breast cancer cells in mice. Micro-CT examination showed that bone loss of the trabecu...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
ConclusionsOverall, our findings proved that EEOD could inhibit breast cancer metastasis by attenuating the expression of Cav-1, highlighting the use of EEOD as an adjunctive therapy for metastatic breast cancer patients. This study also provides novel insights into network pharmacology and bioinformatics analysis as effective tools to illuminate the scientific basis of TCM.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Response rate of 33.3 percent, median response duration of 7.7 months observed in 108 patients
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news
Conditions:   Breast Cancer;   Hormone Dependent Neoplasms;   Adherence to Hormone Therapy Interventions:   Behavioral: " OncoTool " Intervention (MBSR + HT education);   Behavioral: " Oncotool " Control (health +HT education) Sponsor:   Northwestern University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 20 February 2019Source: Journal of Molecular StructureAuthor(s): Gokcen Eren, Esra Emerce, Leyla Acik, Betul Aydin, Fatma GumusAbstractTrans-[Pt(AMBi)2Cl2 (1) in which AMBi is 2-acetoxymethylbenzimidazole, was synthesized and characterized by spectroscopic methods. Novel complex 1 was evaluated for its potential antiproliferative effect against three human cancer cell lines, including HeLa (human cervix cancer), MCF-7 (human breast cancer) and A549 (human non-small-cell lung cancer) in comparison with those of cis-[Pt(AMBi)2Cl2 (2) and cisplatin by means of the MTT assay. Interaction of c...
Source: Journal of Molecular Structure - Category: Molecular Biology Source Type: research
Publication date: Available online 21 February 2019Source: American Journal of Preventive MedicineAuthor(s): Andres McConnon, Kinwah Fung, Aisha Lofters, Stephen W. Hwang, Fiona G. KouyoumdjianIntroductionPrimary care represents an opportunity to improve health for people who experience imprisonment, and screening for colorectal and breast cancer indicate primary care quality. The study objectives were to examine the proportion of people released from provincial correctional facilities who were overdue for colorectal or breast cancer screening on admission to the correctional facility and who were still overdue after 3 yea...
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
THURSDAY, Feb. 21, 2019 -- An antibody-drug conjugate, sacituzumab govitecan-hziy, shows promise in refractory metastatic triple-negative breast cancer, according to a study published in the Feb. 21 issue of the New England Journal of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology